--- title: "Enliven Therapeutics launches $250,000,000 offering" url: "https://aibio.space/news/enliven-therapeutics-launches-250-000-000-offering-then-prices-upsized/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-06-11" section: "Financings" tickers: "NASDAQ:ELVN" source: "https://www.sec.gov/Archives/edgar/data/1672619/000119312526267938/d114232d424b5.htm" summary: "The final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June" --- By the aibio.space news desk. Sources - [Enliven Therapeutics, Inc. 424B5 (2026-06-11)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526267938/d114232d424b5.htm) - [d114232d424b5.htm](https://www.sec.gov/Archives/edgar/data/1672619/000119312526269621/d114232d424b5.htm) - [d152122dex991.htm](https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/d152122dex991.htm) - [Enliven Therapeutics, Inc. 10-K (2026-03-03): business](https://www.sec.gov/Archives/edgar/data/1672619/000119312526088232/elvn-20251231.htm) - [Enliven Therapeutics, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526088232/) [ELVN](https://aibio.space/companies/enliven-therapeutics/) 2026-06-11 # Enliven Therapeutics launches $250,000,000 offering, then prices upsized sale at $37.50 Tickers [ELVN](https://aibio.space/companies/enliven-therapeutics/) The final terms total $399,998,279.17 in shares and pre-funded warrants before underwriting discounts. The offering was expected to close on or about June 15, 2026. ## Key facts - **Company**: Enliven Therapeutics, Inc. (NASDAQ: ELVN) - **News type**: Financings - **Primary source**: [Enliven Therapeutics, Inc. 424B5 (2026-06-11)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526267938/d114232d424b5.htm) *Office towers against a dusk sky. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The offering terms Enliven Therapeutics, Inc. filed a preliminary prospectus supplement on June 11, 2026 for a $250,000,000 offering of common stock and pre-funded warrants. The company called the deal upsized and, in a press release the same day, June 11, 2026, announced pricing. It priced 8,933,334 shares of common stock at $37.50 each, plus pre-funded warrants for up to 1,733,333 shares at $37.499 each. The last reported sale price on Nasdaq was $37.00 on June 10, 2026, so the deal priced above that level. A pre-funded warrant lets an investor pay nearly the full price up front and leave only the $0.001 per share exercise price to pay later. Each warrant is exercisable for one share, does not expire, and can be exercised at any time after issue, subject to an ownership limitation. The offering totals $399,998,279.17 before underwriting discounts and commissions of $24,000,000.75. The use-of-proceeds section puts net proceeds at approximately $376.0 million, or approximately $432.4 million if the underwriters exercise their 30-day option in full. That option covers up to 1,600,000 more shares at the public offering price. ## Who is running the deal Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are joint book-running managers. Mizuho is also a book-running manager, LifeSci Capital is a passive book-running manager, Baird is lead manager and Jones is a manager. The shares are sold under an automatic shelf registration statement on Form S-3ASR that became effective on August 13, 2025. The documents name no placement agent or financial advisor. The underwriters are represented by Cooley LLP of New York. The legal matters section also names Wilson Sonsini Goodrich & Rosati, Professional Corporation, of Palo Alto, California, and says investment funds associated with that firm hold 22,237 shares, less than 1% of the outstanding stock. ## What the trial data show ELVN-001 is a kinase inhibitor designed to hit BCR-ABL, the gene fusion that drives chronic myeloid leukemia (CML). The lead data come from the Phase 1 ENABLE trial. As of March 10, 2026, 161 patients had been enrolled at doses of 10 to 240 mg daily. The group is heavily pretreated: 70% had received three or more prior unique TKIs, and 23% had received five or more. The efficacy figures rest on small groups. In Phase 1b, 69 patients were evaluable for major molecular response (MMR) by 24 weeks, and the overall MMR rate was 54%. In the 80 mg once-daily cohort, 28 patients were evaluable and the rate was 61%. The rate falls with heavier prior treatment: 55% (n=27) for patients with one or two prior TKIs, 32% (n=26) for three or four, and 29% (n=16) for five or more. The figures come from dose cohorts, with no control arm reported. The company says ELVN-001 "was generally well-tolerated." The filing also reports that 6% of patients stopped treatment because of adverse events. Grade 3 or higher treatment-emergent adverse events occurred in 53 of 158 patients (34%). At the 80 mg once-daily dose, 15 of 62 patients (24%) had one. The end-of-Phase 1 meeting with the FDA selected 80 mg once daily as the dose for the Phase 3 trial, ENABLE-2. That trial is expected to randomize patients with CML to ELVN-001 or a physician's choice of an ATP-competitive TKI. The company plans an End-of-Phase 2 meeting with the FDA in the third quarter of 2026 and expects to start ENABLE-2 in the second half of 2026. ## The company's finances The company's 10-K for 2025 reports a net loss of $103.7 million, against $89.0 million in 2024. Research and development expense rose to $85.9 million from $80.8 million. Cash used in operations was $70.3 million for 2025. At the end of 2024 the company held $124.1 million in cash and cash equivalents and $189.3 million in short-term investments. The company says the net proceeds will fund ELVN-001 in ongoing and planned trials across multiple lines of therapy, initial commercial readiness, and working capital. The use-of-proceeds section does not break out a budget for ENABLE-2. The company still has a Phase 3 trial ahead. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ELVN Enliven Therapeutics, Inc. NASDAQ ยท United States Open the starter desk ## More in Financings Financings ### [INmune Bio raises $4.50 million in registered direct offering with warrants](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/) Oct 29, 2026 Financings ### [Lexeo Therapeutics files $300 million shelf registration](https://aibio.space/news/lexeo-therapeutics-files-300-million-shelf-registration/) Oct 29, 2026 Financings ### [ProKidney files $650 million shelf with $200 million Jefferies sales program](https://aibio.space/news/prokidney-files-650-million-shelf-200-million-jefferies-sales-program/) Oct 29, 2026 --- Source page: https://aibio.space/news/enliven-therapeutics-launches-250-000-000-offering-then-prices-upsized/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enliven Therapeutics launches $250,000,000 offering", 2026-06-11, https://aibio.space/news/enliven-therapeutics-launches-250-000-000-offering-then-prices-upsized/